Life sciences

Communications for research-driven organizations have to trace every claim back to the evidence, and in pharma and medical devices that traceability is a legal requirement enforced with growing vigor. The FDA's Office of Prescription Drug Promotion treats influencer and creator content as if the manufacturer produced it, and holds it to the same standards: fair balance between benefit and risk, complete safety information, and no overstatement. On 9 September 2025, HHS and the FDA announced they were sending thousands of warning letters to pharmaceutical companies and issuing roughly 100 cease-and-desist letters over misleading ads, a sharp escalation from just five OPDP letters in all of 2024. We build life sciences work to survive that scrutiny.

Fair balance is the discipline that most creator content fails. Social media is optimized for engagement, which pulls toward benefit-forward, emotionally resonant messaging, exactly the imbalance the FDA penalizes. Presenting risk information with prominence comparable to benefit claims, in the same modality, is hard to do in short-form video and impossible to do by accident. We design life sciences communication so that fair balance is built into the format, and so that every claim maps to the evidence that supports it.

• Claims are cited back to the underlying source.
• Scientific and regulatory review gates publication.
• Plain-language versions are checked as carefully as technical ones.
• Approved language is reused consistently across channels.

The forward view is that regulatory scrutiny of promotional communications in this sector will only intensify, and that the organizations which can show the evidence chain for every claim will be the ones able to use creator channels at all. We treat substantiation and record-keeping as the foundation, because in life sciences a claim that cannot trace back to evidence is not a marketing problem, it is a regulatory one.